Sign in
Mubadala’s Kelix Bio snags four new pharma assets: Mubadala-owned speciality pharma company Kelix Bio acquired four pharma assets from Yas Holding’s GlobalOne Healthcare Holding for an undisclosed sum, according to a statement. The assets include biopharma and IV solutions manufacturing firms Bioventure, Bioventure Healthcare, Gulf Inject, and Wellpharma.
What Kelix bio is getting:
- Bioventure, a UAE-based biopharma firm specializing in biotech and generics;
- Bioventure Healthcare, the region’s top producer of soft gelatin capsules for pharma and supplement products. The firm is currently expanding into oral solids and injectables;
- Gulf Inject, a producer of sterile fluid management therapy, parenteral therapy, and healthcare manufacturing solutions;
- Wellpharma, a leading producer of intravenous and dialysis therapies.
The move comes as Kelix bio is looking to ramp up its UAE and regional presence, the statement reads. The company partnered with Khalifa University of Science and Technology and Mubadala in May to explore new technologies in fields such as oncology, metabolic disorders, and rare diseases.
BACKGROUND- Abu Dhabi sovereign wealth fund Mubadala fully acquired pan-African biopharma platform Kelix Bio in March from Kelix Bio’s co-founders — Development Partners International, British International Investment, and the European Bank for Reconstruction and Development. The value of the transaction was not disclosed.
More on Kelix bio: The company is the first pan-African biopharma platform dedicated to increasing accessibility to essential medication in developing markets. It has previously acquired companies including Egypt’s Adwia, India’s Celon Labs, Morocco’s PHI, and Kelix Bio Malta, bringing its portfolio to span critical medicines accessible in 50+ countries spanning Africa, Latin America, Southeast Asia, and the Middle East.
